Abstract:The use of Antisense Oligonucleotides (ASOs) for re-directing splicing has shown promising results as a therapeutic approach for several diseases. A showcase for this technology comes from work done on the Survival of Motor Neuron 2 (SMN2) gene. SMN2 only generates a small amount of full-length mRNA due to a point mutation in exon 7 that causes it to be predominantly skipped. We have previously identified an 18mer 2′-O-methoxyethyl (MOE) modified ASO that promotes almost complete exon 7 inclusion by targeting ISS-N1, an hnRNP A1/A2-dependent intronic splicing silencer in intron 7. We have extended these findings by evaluating how various chemical modifications of the nucleotide sugar moiety of the 18mer ASO affect SMN2 exon 7 splicing. Unexpectedly, we found that incorporating fluorine at the 2′ position (2′-F) of the ribose sugar caused almost complete exon 7 skipping. This skipping activity is dependent on hybridization to the target pre-mRNA and is still robust when the ASO binding is shifted 3′. Furthermore, the 2′-F ASO causes skipping of exon 7 on chromatin associated RNA. We have explored the mechanisms by which the MOE ASO causes SMN2 exon 7 inclusion and the 2′-F ASO causes exon 7 skipping, by doing pull-down experiments with SMN2 RNA immobilized on magnetic beads. We found that the MOE ASO displaces hnRNPA1/A2 from ISS-N1. The 2′-F ASO is still able to displace hnRNPA1/A2, but the resulting 2′-F ASO-RNA duplex is recognized by Interleukin Enhancer Binding Factor 2 and 3 (ILF2 and ILF3). To determine if ILF2 and ILF3 are responsible for the skipping of exon 7, we reduced their expression with siRNAs. Indeed, reduction of ILF2 and ILF3 expression reversed the 2′-F ASO-mediated exon skipping. When administered to SMN2 transgenic mice, the 2′-F ASO caused SMN2 exon 7 skipping in a variety of tissues. These results demonstrate that ASOs with different chemical modifications can be used to promote exon inclusion or exon skipping by either displacing proteins from the pre-mRNA or by recruiting specific proteins to the heteroduplex.

Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing

Abstracts7th Annual Meeting of the Oligonucleotide Therapeutics SocietyCopenhagen, DenmarkSeptember 8–10, 2011

Targeted blocking of gene splicing can dysregulate intron-embedded microRNAs

Antisense-mediated exon inclusion.

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon.

Peptide Conjugates of a 2'- O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes

ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION

Directed RNase H Cleavage of Nascent Transcripts Causes Transcription Termination

A CRISPR/Cas9 screen reveals proteins at the endosome-Golgi interface that modulate cellular ASO activity

RNA splicing process analysis for identifying antisense oligonucleotide inhibitors with padlock probe-based isothermal amplification.

Mechanistic Insights into ASO-RNA Complexation: Advancing Antisense Oligonucleotide Design Strategies

Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation

TSUNAMI: an Antisense Method to Phenocopy Splicing-Associated Diseases in Animals

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

Inhibition of the Expression of Oncogene SRSF3 by Blocking an Exonic Splicing Suppressor with Antisense Oligonucleotides.

Going nuclear: Improved antisense oligonucleotide activity through conjugation with a nuclear importer

Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application

Antisense Oligonucleotide Technology Can Be Used to Investigate a Circular but Not Linear RNA-mediated Function for Its Encoded Gene Locus.

Epigenetic Regulation of Alternative Splicing.

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons